Ocular toxicity associated with systemic drug therapy

Current Opinion in Ophthalmology

Volumn 10, Issue 6, 1999, Pages 438-446

  Moorthy, Ramana S ^a,c   Valluri, Shailaja ^b  

^a Associated Vitreoretinal and Uveitis Consultants   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CHLOROQUINE; CIDOFOVIR; CORTICOSTEROID; HYDROXYCHLOROQUINE; LATANOPROST; METIPRANOLOL; MEVINOLIN; PHOSPHONIC ACID DERIVATIVE; RIFABUTIN; SILDENAFIL; SIMVASTATIN; SULFONAMIDE; TAMOXIFEN; TAMOXIFEN CITRATE; VIGABATRIN;

ARTICLE; CATARACT; EYE TOXICITY; HUMAN; ISCHEMIC OPTIC NEUROPATHY; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULOPATHY; UVEITIS; VISUAL FIELD DEFECT;

ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY; ENZYME INHIBITORS; EYE; EYE DISEASES; HUMANS; VISUAL FIELDS;

EID: 0032719251     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199912000-00012     Document Type: Article

References (37)

1. 1 Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
2. 2 Moorthy RS, Valluri S. Jampol LM: Drug-induced uveitis. Surv Ophthalmol 1998, 42:557-570. Reviews systemic, topical, and intracameral drugs and systemic vaccines and whether they truly cause uveitis. Summarized most important findings in Table 1.
3. 3 Koneru PB, Lien EJ, Koda RT: Oculotoxicities of systemically administered drugs. J Ocul Pharmacol 1986, 2:385-404.
4. 4 Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al.: Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Ophthalmology 1997, 104:539-544.
5. 5 Davis JL, Taskintuna I, Freeman WR, et al.: Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997, 115:733-737.
6. 6 Friedberg DN: Hypotony and visual loss wilh intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol 1997, 115:801-802.
7. 3. Despite iritis and hypotony, medication was discontinued in only one patient (12%).
8. 8 Taskintuna I, Rahhal FM, Rao NA, et al.: Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997, 104:1827-1837.
9. 9 Taskintuna I, Banker AS, Rao NA, et al.: An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res 1997, 64:795-806.
10. 10 Marmor MF: Sildenafil (Viagra) and ophthalmology [editorial]. Arch Ophthalmol 1999, 117:518-519. This paper summarizes the findings of Vobig et al. (Lancet 1999, 353:375), Wallis ef al. (Ophthalmic Res 1998, 30(suppl 1):68), and Zrenner (Lancet 1999, 353: 340-341). This editorial makes a strong argument for cautious use of sildenafil, especially in patients with a family history of retinitis pigmentosa.
11. 11 Vobig MA, Klotz T, Staak M, et al.: Retinal side-effects of sildenafil. Lancet 1999, 353:375.
12. 12 Wallis RM, Leishman D, Pullman L, et al.: Effects of sildenafil on retinal histopathology and electroretinogram (ERG) in dogs [abstract]. Ophthalmic Res 1998, 30(suppl 1):68.
13. 13 Zrenner E: No cause for alarm over retinal side-effects of sildenafil. Lancet 1999, 353:340-341.
14. 14 Fisher RS, Kerrigan JF: Vigabatrin toxicity. In Antiepileptic Drugs, edn 4, Edited by Levy RH, Mattson RH, Meldrum BS, et al. New York: Raven Press; 1995:931-939.
15. 15 Eke T, Talbot JF, Lawden MC: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:180-181.
16. 16 Blackwell N, Hayllar J, Kelly G: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:1694.
17. 17 Harding GF: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:1694.
18. 18 Wilson EA, Brodie MJ: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:1693.
19. 19 Wong IC, Mawer GE, Sander JW: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:1693-1694.
20. 20 Krauss GL, Johnson MA, Miller NR: Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998, 50:614-618. This paper explains in detail the reason for visual field constriction with vigabatrin, namely retinal cone dysfunctions. Objective and detailed documentation helped to establish causality.
21. 21 Ah-Song R, Sasco AJ: Tamoxifen and ocular toxicity. Cancer Detect Prev 1997, 21:522-531.
22. 22 Tang R, Shields J, Schiffman J, et al.: Retinal changes associated with tamoxifen treatment for breast cancer. Eye 1997, 11:295-297.
23. 23 Nayfield SG, Gorin MB: Tamoxifen-associated eye disease: a review. J Clin Oncol 1996, 14:1018-1026.
24. 24 Pavlidis NA, Petris C, Briassoulis E, et al.: Clear evidence that long-term, low-dose tamoxifen can induce ocular toxicity: a prospective study of 63 patients. Cancer 1992, 69:2961-2964.
25. 25 Kaiser-Kupfer MI, Kupfer C, Rodriguez MM: Tamoxifen retinopathy: a clinico-pathologic report. Ophthalmology 1981, 88:89-93.
26. 26 Easterbrook M: Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin 1999, 39:49-57. Summarizes the need for Amsler grid self-monitoring and every-6-month ophthalmologic evaluations for patients being treated with hydroxychloroquine. Toxicity may be limited when dosage stays at less than 6.5 mg/kg/d. Daily dosage is more important than cumulative dosage in the development of retinal toxicity.
27. 27 Easterbrook M: Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992, 27:237-239.
28. 28 Spalton DJ: Retinopathy and antimalarial drugs. Lupus 1996, 5(suppl):s70-s72.
29. 29 Rynes RI: Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996, 5(suppl):s73-s74.
30. 30 Silman A, Shipley M: Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997, 36:599-601.
31. 31 Rosenthal AR, Kolb H, Bergsma D, et al.: Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978, 17:1158-1175.
32. 32 Mantyjarvi M, Tuppurainen Klkaheimo K: Ocular side effects of amiodarone. Surv Ophthalmol 1998, 42:360-366. Summarizes the important toxicities of keratopathy, cataracts, optic neuropathy, and rare maculopathy. Both daily and cumulative dosage are important in development of ocular toxicity.
33. 33 Mindel JM: Amiodarone and optic neuropathy: a medicolegal issue [editorial]. Surv Ophthalmol 1998, 42:358-359.
34. 34 Feiner LA, Younge BR, Kazmier JF, et al.: Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987, 62:702-717.
35. 35 Macaluso DC, Shults WT, Fraunfelder FT: Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999, 127:610-612. Important collection of data on the pattern of amiodarone-associated optic neuropathy. The pattern involves more insidious onset, longer duration of disk odema, more often bilateral, and less likely to produce profound visual loss than AION.
36. 36 Gerson RJ, MacDonald JS, Alberts AW, et al.: On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Ros 1990, 50:65-78.
37. 37 Pedersen TR, Berg K, Cook TJ, et al.: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996, 156:2085-2092.